Milestone Pharmaceuticals (MIST) provided a corporate update and outlined its strategic priorities for 2025. CARDAMYST for Paroxysmal Supraventricular Tachycardia: FDA Prescription Drug User Fee Act target date is March 27, 2025; Launch in PSVT targeted for mid-2025. Etripamil for patients with atrial fibrillation with rapid ventricular rate: Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST: